Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Insogna

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
The Journal of Clinical Endocrinology and Metabolism|April 29, 2015
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23Erik A Imel, Xiaoping Zhang, Mary D Ruppe, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 25, 2016
Hypophosphatemia promotes lower rates of muscle ATP synthesisDominik H Pesta, Dimitrios N Tsirigotis, Douglas E Befroy, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosisDebayan Dasgupta, Mark J Wee, Monica Reyes, et al.
Calcified Tissue International|August 4, 2022
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 StudyMaria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, et al.
Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.
RMD Open|September 22, 2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Anthony A Portale, Maria Luisa Brandi, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
The Journal of Clinical Endocrinology and Metabolism|April 29, 2015
Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23Erik A Imel, Xiaoping Zhang, Mary D Ruppe, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 25, 2016
Hypophosphatemia promotes lower rates of muscle ATP synthesisDominik H Pesta, Dimitrios N Tsirigotis, Douglas E Befroy, et al.
Journal of the American Society of Nephrology : JASN|April 5, 2014
Mutations in SLC34A3/NPT2c are associated with kidney stones and nephrocalcinosisDebayan Dasgupta, Mark J Wee, Monica Reyes, et al.
Calcified Tissue International|August 4, 2022
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 StudyMaria Luisa Brandi, Suzanne Jan de Beur, Karine Briot, et al.
Calcified Tissue International|June 6, 2019
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A Portale, Thomas O Carpenter, Maria Luisa Brandi, et al.
RMD Open|September 22, 2021
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Anthony A Portale, Maria Luisa Brandi, et al.
Pageof 6